跳至主要内容
临床试验/NCT04281004
NCT04281004已完成1 期

A Phase I/II Randomized, Double-Masked Placebo-Controlled Study For Determining The Safety Of Processed Amniotic Fluid (PAF) Drops After Photorefractive Keratectomy

University of Utah2 个研究点 分布在 1 个国家目标入组 61 人开始时间: 2020年7月10日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
61
试验地点
2
主要终点
Safety - Adverse Events Including Serious Adverse Events

研究概览

简要总结

This is a randomized, double-masked, placebo-controlled study to determine the safety of pAF in patients who undergo PRK.

详细描述

Photorefractive Keratectomy (PRK) is a common elective surgery used to correct refractive errors. We propose that amniotic fluid drops may be beneficial in promoting ocular surface healing following PRK. Purified amniotic fluid (pAF) contains anti-inflammatory, anti-microbial and regenerative factors similar to solid amniotic membrane. Individual patients will be randomized to one of two post-operative drop regimens, control eyes that will receive placebo saline solution (NaCl 0.9%, Baxter Medical), and study eyes that will receive pAF four times daily for seven days.

This is a randomized, double-masked, placebo-controlled study to determine

  • the safety of pAF in patients who undergo PRK
  • if pAF hastens re-epithelialization following PRK compared to placebo
  • if pAF reduces post-operative pain following PRK compared to placebo
  • if pAF affects visual outcome following PRK compared to placebo
  • if pAF affects ocular surface staining and corneal regularity following PRK compared to placebo

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Safety - Adverse Events Including Serious Adverse Events

时间窗: Up to 12 months after the last study dose

Ocular adverse events using MedDRA and CTCAE and serious adverse events

次要结局

  • Time to Complete Re-epithelization(Post-operative days 1 - 8)
  • Pain in Each Eye(Post-operative days 1 - 8)
  • Uncorrected Visual Acuity(Post-operative months 1, 3, 6, and 12)
  • Count of Participants Who Reported Oral Pain Medication Usage(Post-operative days 1 - 8)
  • Corneal Staining in Each Eye(Post-operative months 1, 3, 6, and 12)
  • Corneal Surface Regularity(Post-operative months 1, 3, 6, and 12)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mark Mifflin

MD

University of Utah

研究点 (2)

Loading locations...

相似试验

Processed Amniotic Fluid (PAF) Drops After... | 临床试验